Table 1 Analysis of 31P-MRS-detected metabolic changes following inhibition with MK-2206 in

From: Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma

 

PC3

 

6 h (5xGI50)

P

12 h (5xGI50)

P

24 h (5xGI50)

P

24 h (3xGI50)

P

PE

62 ± 16

0.008

47 ± 11

0.001

23 ± 16

0.0001

43 ± 26

0.01

PC

74 ± 14

0.02

78 ± 11

0.02

69 ± 13

0.001

71 ± 5

0.0004

GPE

66 ± 34

ns

50 ± 12

0.001

320 ± 104

0.005

153 ± 40

ns

GPC

32 ± 16

0.001

36 ± 11

0.0003

225 ± 63

0.007

121 ± 27

ns

PCr

74 ± 28

ns

54 ± 31

0.04

38 ± 24

0.007

46 ± 24

0.01

NTP

63 ± 17

0.01

56 ± 12

0.002

68 ± 18

0.005

82 ± 11

0.03

 

HT29

 

24 h (5xGI50)

P

PE

60 ± 9

0.001

PC

67 ± 6

0.0001

GPE

132 ± 26

0.04

GPC

169 ± 31

0.004

PCr

59 ± 8

0.0001

NTP

89 ± 7

0.02

  1. Data are expressed as %T/C and presented as the mean ± SD, n ≥ 4
  2. Two-tailed unpaired t test was used to compare results in treated cells to controls within the same time-point
Back to article page